You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202311 - 202320 of 207725 results
  1. Highly-Multiplexed Accurate HLA Typing using PAP and Digital Bead Technologies

    SBC: MAXWELL SENSORS INC.            Topic: N/A

    Location MAXWELL SENSORS, INC. 10020 PIONEER BLVD, STE 103 Santa Fe Springs, CA 90670 United States 1R41HL083573-01 $215 235.00 2 006 Highly-Multiplexed Accurate HLA Typing using PAP and Digital Bead Technologies Department of Health and Human Services Na ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Reagentless Immunosensors Based on Biofunctionalized Nanotubes

    SBC: EIC LABORATORIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our aim is to develop an inexpensive and portable nanotechnology-based immunosensor and instrument platform for rapid detection of presence or exposure to bioterror agents in air, water, contaminated surfaces, forensic samples, food and body fluids through identification of protein toxins and microorganisms. The proposed approach employs single or multiple coni ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Cancer dual-targeting of an infectivity-enchanced CRAd

    SBC: VECTORLOGICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A number of characteristics of the Adenovirus type 5 (Ad5) make it an optimal gene therapy/virotherapy vector suitable for a wide array of cancer therapeutic approaches. Despite these advantages, overall ifficacy remains limited by sub-optimal adenovirus delivery to cancer tissues. One conceptual approach to overcome this limitation is to achieve an amplificati ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation

    SBC: CERUS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence. To address these problems, we are developing a vaccination methodology using a non-replicating but highly immunogenic Listeria monocytogenes (Lm) vector. When an Lm vaccine ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. New APEX diagnostic for hereditary sensorineural hearing loss

    SBC: APEX DX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In developed countries, approximately 1:1000 children are born deaf and approximately 1:300 children are born with some lesser degree of hearing loss. At least 50% of the deafness and hearing impairment is likely to be attributable to genetic factors, with a large number of genes involved in the pathogenesis. The molecular genetic basis for the majority of case ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Ultrasound Guidance for a Laparoscopic Surgical Robot

    SBC: INTUITIVE SURGICAL            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal represents the second phase of an STTR partnership involving Intuitive Surgical Systems and Johns Hopkins University. Phase I demonstrated the feasibility and promise of integrating laparoscopic ultrasound (LUS) capability into daVinci. Phase II will develop a complete, integrated application environment and testbed surgical applications for LUS-g ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. IPformatics: An Integrated Knowledgebase of Patent Claims and Genomic Data

    SBC: BIOSPHEREX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a proposal to create a knowledgebase of the intellectual property rights that exist in human genes. When completed, the knowledgebase will have three distinct elements: (1) a searchable sequence component that contains nucleotide and amino sequences listed in U.S. Patents; (2) a gene patent component that links each human gene with the U.S. patents whic ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. A Stage-Based Tailored Support Tool for Alcohol Counsel

    SBC: SILVERCHAIR SCIENCE+COMMUNICATION, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcohol-related problems are costly, but not routinely addressed in primary care where 100+ million people receive their usual source of care. Moreover patients are motivated to act on the health behavior advice of their primary care physicians. We propose to develop a state-of-the-art computer software application to enhance clinician effectiveness in diagnosi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Cell-based screening of combinatorial siRNA libraries

    SBC: CYNTELLECT, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): RNA interference (RNAi) is a specific post-transcriptional gene silencing pathway mediated by intracellular dsRNAs of 21-23 bp in length known as small interfering RNA (siRNA). Since the recent discovery of effective siRNA-mediated gene silencing in mammalian cells, there has been significant validation and enormous interest in the approach from both academic a ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government